Longitudinal Multimodal Response Assessment During Neoadjuvant Treatment of Rectal Cancer
Launched by JENA UNIVERSITY HOSPITAL · Aug 30, 2022
Trial Information
Current as of July 12, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new way to assess how well treatment is working for patients with locally advanced rectal cancer. It combines different methods to monitor patients' responses to therapy, which could help doctors adjust treatments early on if needed. The goal is to create a model that can predict how patients will respond to non-surgical treatments like radiation therapy.
To participate in this study, you need to have locally advanced rectal cancer (stages II or III) and meet certain health criteria, such as having no severe heart or lung issues, and no major liver or kidney problems. If you join the trial, you will undergo various assessments during your treatment to help understand your response better. This study is currently recruiting participants aged 65 and older, and everyone is welcome to apply, regardless of gender. It's an exciting opportunity that could lead to improved treatment strategies for rectal cancer in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • locally advanced rectal cancer (LARC): UICC Stage II/III
- • no severe cardiac or lung disease
- • no severe hepatic disorders (liver enzymes \<2.5 NR) or restrictions of renal function (GFR \> 30ml/min)
- • no severe cytopenia (Neutrocytes \>= 3 Gpt/l; Thrombocytes \>= 100 Gpt/l; Hemoglobin \>6mmol/l)
- • no homozygotic DPD deficiency
- • no other neoplasms requiring therapy
- • no earlier radiotherapy of the pelvis or earlier chemotherapy
- • no contraindications for MRI
About Jena University Hospital
Jena University Hospital is a leading academic medical center located in Jena, Germany, renowned for its commitment to advancing healthcare through innovative research and high-quality clinical care. As a prominent sponsor of clinical trials, the hospital leverages its multidisciplinary expertise and state-of-the-art facilities to conduct rigorous studies aimed at evaluating new treatments, medical devices, and healthcare interventions. With a strong focus on collaboration between clinicians, researchers, and academic partners, Jena University Hospital plays a pivotal role in translating scientific discoveries into tangible benefits for patients, ultimately enhancing the quality of medical practice and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jena, , Germany
Patients applied
Trial Officials
Andrea Wittig-Sauerwein, MD
Principal Investigator
Department for Radiotherapy and Radiooncology, Jena University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials